30.32 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||30.09 x 900|
|Ask||30.17 x 800|
|Day's Range||28.64 - 30.60|
|52 Week Range||24.05 - 55.12|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.75|
(Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.
Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Seattle's biotech community has a reputation for developing companies that are eventually acquired and that has restricted its growth. But a few companies are well-positioned to change that narrative.
SEATTLE, Nov. 12, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended September 30,.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the third quarter of 2019 after market close on Tuesday, November 12, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3698520). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
If you want to know who really controls Adaptive Biotechnologies Corporation (NASDAQ:ADPT), then you'll have to look...
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.
Adaptive Biotechnologies Corporation (ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) across multiple drug development programs within the Amgen hematology portfolio.
SEATTLE, Aug. 13, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019..
(Bloomberg) -- Shares in three of the year’s hottest IPOs, Uber Technologies Inc., Revolve Group Inc. and Fastly Inc., plunged Friday as the latest batch of newly listed companies reported some of the most disappointing results this earnings season.Uber shares ended Friday 6.8% lower after the ride-hailing company missed sales estimates. Revolve fell 15.6% after the fashion e-tailer reported earnings below expectations. And Fastly, which saw its shares dip below its IPO price intraday, declined 18.1% after reporting lighter than expected margins.The disappointment spread to other IPOs that have not even reported yet, with RealReal Inc. shares tumbling 23% to below its IPO price of $20.Call it an upset, given the hype that tends to follow IPOs. Among the nearly 20 freshly listed companies that reported earnings this week, the majority fell in the next session. IPOs are rising 0.2% on average following reports, lagging behind S&P 500 stocks, which climbed 5.3% on average, according to data compiled by Bloomberg.Other newcomers on deck to report earnings include Adaptive Biotechnologies Corp., Greenlane Holdings Inc., RealReal Inc., and Grocery Outlet Holding Inc. They are among the more well-received IPOs of this year with stocks that opened at least 40% above their offer prices. All are first-time reporters.Cross-border IPOs will be tested as well when China’s big brands So-Young International Inc. and Luckin Coffee Inc. do their show-and-tell.(Updates shares in 1st and 2nd paragraphs, adds RealReal shares in 3rd.)\--With assistance from Drew Singer.To contact the reporter on this story: Crystal Kim in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Jennifer Bissell-Linsk, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
SEATTLE, Aug. 07, 2019 -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the.
Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3095467). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.